Angioedema

Critical Care Medicine

Volumn 45, Issue 4, 2017, Pages 725-735

  Loverde, Daniel ^a   Files, Daniel Clark ^a   Krishnaswamy, Guha ^a,b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

acquired angioedema; bradykinin B2 receptor antagonists; hereditary angioedema type III; hereditary angioedema types I and II; kallikrein kinin system

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; EPINEPHRINE; FRESH FROZEN PLASMA; GLUCOCORTICOID; HISTAMINE; ICATIBANT; BRADYKININ B2 RECEPTOR ANTAGONIST; KALLIKREIN; PEPTIDE; RECOMBINANT PROTEIN; SERPING1 PROTEIN, HUMAN;

ACUTE ABDOMEN; ALLERGY; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTIFICIAL VENTILATION; CEREBROVASCULAR ACCIDENT; ENDOTRACHEAL INTUBATION; GENITAL EDEMA; HOSPITALIZATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; KALLIKREIN KININ SYSTEM; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATION CONTROL; REVIEW; URTICARIA; ANALOGS AND DERIVATIVES; ANGIOEDEMA; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; GENETICS;

AIRWAY MANAGEMENT; ANGIOEDEMA; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONISTS; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; CRITICAL CARE; HUMANS; KALLIKREINS; PEPTIDES; RECOMBINANT PROTEINS;

EID: 85016203807     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002281     Document Type: Review

References (120)

1. Jose J, Zacharias J, Craig T: Review of select practice parameters, evidence-based treatment algorithms, and international guidelines for hereditary angioedema. Clin Rev Allergy Immunol 2016; 51:193-206
2. Davis-Lorton M: An update on the diagnosis and management of hereditary angioedema with abnormal C1 inhibitor. J Drugs Dermatol 2015; 14:151-157
3. Schulkes KJ, Van den Elzen MT, Hack EC, et al: Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of nonhereditary angioedema: A retrospective study. Clin Transl Allergy 2015; 5:5
4. Hofman ZL, Relan A, Hack CE: Hereditary angioedema attacks: Local swelling at multiple sites. Clin Rev Allergy Immunol 2016; 50:34-40
5. Tse K, Zuraw BL: Recognizing and managing hereditary angioedema. Cleve Clin J Med 2013; 80:297-308
6. Saleh H, Embry S, Nauli A, et al: Anaphylactic reactions to oligosaccharides in red meat: A syndrome in evolution. Clin Mol Allergy 2012; 10:5
7. Miller CW, Guha B, Krishnaswamy G: Exercise-induced anaphylaxis: A serious but preventable disorder. Phys Sportsmed 2008; 36:87-94
8. Ismail S, Cheng L, Grigoriadou S, et al: Lesson of the month 2: The limitations of steroid therapy in bradykinin-mediated angioedema attacks. Clin Med (Lond) 2015; 15:101-103
9. Manson AL, Dempster J, Grigoriadou S, et al: Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema. Eur J Dermatol 2014; 24:28-34
10. Patel NS, Fung SM, Zanichelli A, et al: Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. Allergy Asthma Proc 2013; 34:72-77
11. Bygum A, Broesby-Olsen S: Rapid resolution of erythema marginatum after icatibant in acquired angioedema. Acta Derm Venereol 2011; 91:185-186
12. Zanichelli A, Badini M, Nataloni I, et al: Treatment of acquired angioedema with icatibant: A case report. Intern Emerg Med 2011; 6:279-280
13. Weller K, Magerl M, Maurer M: Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol 2011; 25:119-120
14. Branellec A, Bouillet L, Javaud N, et al; French National Reference Center for Angioedema (CREAK): Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol 2012; 32:936-941
15. Hassan A, Amarger S, Tridon A, et al: Acquired angioedema responding to rituximab. Acta Derm Venereol 2011; 91:733-734
16. Motosue MS, Howard MT, Butterfield JH: Rituximab in a patient with splenic marginal zone lymphoma and acquired angioedema. Ann Allergy Asthma Immunol 2016; 116:472-473
17. Levi M, Hack CE, van Oers MH: Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med 2006; 119:e3-e5
18. Rottem M, Mader R: Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis. J Rheumatol 2010; 37:209
19. Faisant C, Boccon-Gibod I, Mansard C, et al: Idiopathic histaminergic angioedema without wheals: A case series of 31 patients. Clin Exp Immunol 2016; 185:81-85
20. Krishnaswamy G, Youngberg G: Acute and chronic urticaria. Challenges and considerations for primary care physicians. Postgrad Med 2001; 109:107-8, 111
21. Gravante C, Carucci L, Bova M, et al: Prophylactic treatment with plasma-derived C1 inhibitor in idiopathic non-histaminergic angioedema. Pediatr Allergy Immunol 2016; 27:658-659
22. Stahl MC, Harris CK, Matto S, et al: Idiopathic nonhistaminergic angioedema successfully treated with ecallantide, icatibant, and C1 esterase inhibitor replacement. J Allergy Clin Immunol Pract 2014; 2:818-819
23. Berry A, Firszt R: Successful treatment of idiopathic angioedema with ecallantide. J Allergy Clin Immunol Pract 2013; 1:297-298
24. Dy TB, Rasheed M, Parikh P, et al: Resolution of an acute attack of idiopathic angioedema with ecallantide. Ann Allergy Asthma Immunol 2013; 111:224-226
25. Schneider L, Lumry W, Vegh A, et al: Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007; 120:416-422
26. Montinaro V, Loizzo G, Zito A, et al: Successful treatment of a facial attack of angioedema with icatibant in a patient with idiopathic angioedema. Am J Emerg Med 2013; 31:1295.e5-1295.e6
27. Colás C, Montoiro R, Fraj J, et al: Nonhistaminergic idiopathic angioedema: Clinical response to icatibant. J Investig Allergol Clin Immunol 2012; 22:520-521
28. Del Corso I, Puxeddu I, Sardano E, et al: Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant. Ann Allergy Asthma Immunol 2012; 108:460-461
29. Loffredo S, Bova M, Suffritti C, et al: Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema. Allergy 2016; 71:989-996
30. Bork K: A decade of change: Recent developments in pharmacotherapy of hereditary angioedema (HAE). Clin Rev Allergy Immunol 2016; 51:183-192
31. Gadek JE, Hosea SW, Gelfand JA, et al: Replacement therapy in hereditary angioedema: Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 302:542-546
32. Kunschak M, Engl W, Maritsch F, et al: A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38:540-549
33. Waytes AT, Rosen FS, Frank MM: Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334:1630-1634
34. Craig TJ, Levy RJ, Wasserman RL, et al: Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124:801-808
35. Zuraw BL, Busse PJ, White M, et al: Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363:513-522
36. Zuraw BL, Kalfus I: Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012; 125:938. e1-938.e7
37. Gandhi PK, Gentry WM, Bottorff MB: Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: Investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012; 32:902-909
38. Cruz MP: Conestat alfa (ruconest): First recombinant c1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema. P T 2015; 40:109-114
39. Moldovan D, Bernstein JA, Cicardi M: Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. Immunotherapy 2015; 7:739-752
40. Feussner A, Kalina U, Hofmann P, et al: Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Transfusion 2014; 54:2566-2573
41. Kawalec P, Holko P, Paszulewicz A: Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-Threatening angioedema attacks in patients with hereditary angioedema. Postepy Dermatol Alergol 2013; 30:152-158
42. Duffey H, Firszt R: Management of acute attacks of hereditary angioedema: Role of ecallantide. J Blood Med 2015; 6:115-123
43. Levy RJ, Lumry WR, McNeil DL, et al: EDEMA4: A phase 3, doubleblind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104:523-529
44. Cicardi M, Levy RJ, McNeil DL, et al: Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363:523-531
45. Cicardi M, Banerji A, Bracho F, et al: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532-541
46. Lumry WR, Farkas H, Moldovan D, et al: Icatibant for multiple hereditary angioedema attacks across the controlled and open-label extension phases of FAST-3. Int Arch Allergy Immunol 2015; 168:44-55
47. Lumry WR, Li HH, Levy RJ, et al: Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107:529-537
48. Warrier MR, Copilevitz CA, Dykewicz MS, et al: Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol 2004; 92:573-575
49. Andersen MF, Longhurst HJ, Rasmussen ER, et al: How not to be misled by disorders mimicking angioedema: A review of pseudoangioedema. Int Arch Allergy Immunol 2016; 169:163-170
50. Copeland B, Aljitawi O, Fitzgerald SM, et al: A patient with facial and neck swelling, dyspnea, and dysphagia. Ann Allergy Asthma Immunol 2005; 95:510-517
51. Feldman MF, Khan DA, Brown ES, et al: Factitious angioedema: A mimic of refractory "angioedema". J Allergy Clin Immunol Pract 2014; 2:795-797
52. Bahna SL, Oldham JL: Munchausen stridor-A strong false alarm of anaphylaxis. Allergy Asthma Immunol Res 2014; 6:577-579
53. Patterson R, Schatz M, Horton M: Munchausen's stridor: Non-organic laryngeal obstruction. Clin Allergy 1974; 4:307-310
54. Raškovic S, Bolpacic J, Peric Popadic A, et al: Clinical characteristics and treatment of Melkersson-Rosenthal syndrome-overview of six patients. Med Pregl 2015; 68:401-404
55. Martinez-Saguer I, Farkas H: Erythema marginatum as an early symptom of hereditary angioedema: Case report of 2 newborns. Pediatrics 2016; 137:e20152411
56. Ghably J, Saleh H, Vyas H, et al: Paul Ehrlich's mastzellen: A historical perspective of relevant developments in mast cell biology. Methods Mol Biol 2015; 1220:3-10
57. Krishnaswamy G, Ajitawi O, Chi DS: The human mast cell: An overview. Methods Mol Biol 2006; 315:13-34
58. Krishnaswamy G, Kelley J, Johnson D, et al: The human mast cell: Functions in physiology and disease. Front Biosci 2001; 6:D1109-D1127
59. Bochner BS, Friedman B, Krishnaswami G, et al: Episodic eosinophilia-myalgia-like syndrome in a patient without L-Tryptophan use: Association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol 1991; 88:629-636
60. Guha B, Youngberg G, Krishnaswamy G: Urticaria and urticarial vasculitis. Compr Ther 2003; 29:146-156
61. Mukkamala R, Baban N, Krishnaswamy G, et al: Persistent urticarial eruption in an asthmatic patient. Ann Allergy Asthma Immunol 1996; 77:359-364
62. Bork K, Wulff K, Witzke G, et al: Antihistamine-resistant angioedema in women with negative family history: Estrogens and F12 gene mutations. Am J Med 2013; 126:1142.e9-1142.14
63. Bork K, Barnstedt SE, Koch P, et al: Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356:213-217
64. Bork K: Hereditary angioedema with normal C1 inhibitor. Immunol Allergy Clin North Am 2013; 33:457-470
65. Iturri CF, Gonzalez UA, Tamayo MG, et al: [Prophylactic use of icatibant before tracheal intubation of a patient with hereditary angioedema type III. (A literature review of perioperative management of patients with hereditary angioedema type III)]. Rev Esp Anestesiol Reanim 2014; 61:375-381
66. Bouillet L, Boccon-Gibod I, Ponard D, et al: Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol 2009; 103:448
67. Icatibant for Patients with Type III Hereditary Angioedema: A Review of Clinical Effectiveness and Harms. Canadian Agency for Drugs and Technologies in Health. 2014. Available at: http://www.ncbi.nlm.nih. gov/pubmedhealth/PMH0072185/. Accessed February 6, 2014
68. Cronin JA, Maples KM: Treatment of an acute attack of type III hereditary angioedema with ecallantide. Ann Allergy Asthma Immunol 2012; 108:61-62
69. Bork K, Wulff K, Hardt J, et al: Hereditary angioedema caused by missense mutations in the factor XII gene: Clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009; 124:129-134
70. Kim SJ, Brooks JC, Sheikh J, et al: Angioedema deaths in the United States, 1979-2010. Ann Allergy Asthma Immunol 2014; 113:630-634
71. Bas M, Greve J, Strassen U, et al: Angioedema induced by cardiovascular drugs: New players join old friends. Allergy 2015; 70:1196-1200
72. Javaud N, Charpentier S, Lapostolle F, et al: Angiotensin-converting enzyme inhibitor-induced angioedema and hereditary angioedema: A comparison study of attack severity. Intern Med 2015; 54:2583-2588
73. Cicardi M, Aberer W, Banerji A, et al; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology): Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69:602-616
74. Zuraw BL, Banerji A, Bernstein JA, et al; US Hereditary Angioedema Association Medical Advisory Board: US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013; 1:458-467
75. Fuse T, Nakada TA, Taniguchi M, et al: Cardiac arrest due to airway obstruction in hereditary angioedema. Am J Emerg Med 2015; 33:1840.e1-1840.e2
76. Desai HG, Shah SS: Recurrent intestinal obstruction with acquired angio-oedema, due to C1-esterase inhibitor deficiency. J Assoc Physicians India 2014; 62:524-525
77. Belkhouribchia J, Backaert T, Neyrinck S: Isolated intestinal angioedema in the emergency department. J Emerg Med 2016; 50:660-662
78. Berger TD, Garty BZ: Hereditary angioedema presenting as recurrent acute pancreatitis. Pediatrics 2016; 137:e20150620
79. Farkas H, Kohalmi KV, Veszeli N, et al: Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy Asthma Proc 2016; 37:164-170
80. Ali MA, Borum ML: Hereditary angioedema: What the gastroenterologist needs to know. Clin Exp Gastroenterol 2014; 7:435-445
81. Craig TJ, Bernstein JA, Farkas H, et al: Diagnosis and treatment of bradykinin-mediated angioedema: Outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol 2014; 165:119-127
82. Bork K, Wulff K, Witzke G, et al: Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy 2015; 70:1004-1012
83. Bork K: An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol 2014; 14:354-362
84. Bork K: Angioedema. Immunol Allergy Clin North Am 2014; 34:23-31
85. Urnoski E, Grillo A, Rosini JM: Use of C1 inhibitor for angiotensinconverting enzyme (ACE) inhibitor-induced angioedema decreases mechanical ventilation time. J Emerg Med 2015; 49:e173-e175
86. Javaud N, Achamlal J, Reuter PG, et al: Angioedema related to angiotensin-converting enzyme inhibitors: Attack severity, treatment, and hospital admission in a prospective multicenter study. Medicine (Baltimore) 2015; 94:e1939
87. Greve J, Bas M, Hoffmann TK, et al: Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 2015; 125:E198-E202
88. Rasmussen ER, Bygum A: ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate. BMJ Case Rep 2013; 2013:1-3
89. Bernstein JA, Moellman JJ, Collins SP, et al: Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. Ann Allergy Asthma Immunol 2015; 114:245-249
90. Lewis LM, Graffeo C, Crosley P, et al: Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: A multicenter, randomized, controlled trial. Ann Emerg Med 2015; 65:204-213
91. Bas M, Greve J, Stelter K, et al: A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 2015; 372:418-425
92. Bas M, Greve J, Stelter K, et al: Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: A case series. Ann Emerg Med 2010; 56:278-282
93. Bova M, Guilarte M, Sala-Cunill A, et al: Treatment of ACEI-related angioedema with icatibant: A case series. Intern Emerg Med 2015; 10:345-350
94. Zuraw BL, Christiansen SC: How we manage persons with hereditary angioedema. Br J Haematol 2016; 173:831-843
95. Zuraw BL, Bork K, Binkley KE, et al: Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy Asthma Proc 2012; 33(Suppl 1):S145-S156
96. Zuraw BL, Bernstein JA, Lang DM, et al; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology: A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensinconverting enzyme inhibitor-Associated angioedema. J Allergy Clin Immunol 2013; 131:1491-1493
97. Cicardi M, Bork K, Caballero T, et al; HAWK (Hereditary Angioedema International Working Group): Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 2012; 67:147-157
98. Cicardi M, Zanichelli A: Acquired angioedema. Allergy Asthma Clin Immunol 2010; 6:14
99. Tai S, Mascaro M, Goldstein NA: Angioedema: A review of 367 episodes presenting to three tertiary care hospitals. Ann Otol Rhinol Laryngol 2010; 119:836-841
100. McCormick M, Folbe AJ, Lin HS, et al: Site involvement as a predictor of airway intervention in angioedema. Laryngoscope 2011; 121:262-266
101. Kieu MC, Bangiyev JN, Thottam PJ, et al: Predictors of airway intervention in angiotensin-converting enzyme inhibitorinduced angioedema. Otolaryngol Head Neck Surg 2015; 153:544-550
102. Kupfer Y, Ramachandran K, Tessler S: ACE inhibitor-induced angioedema in elderly African American females requiring tracheostomy. J Natl Med Assoc 2010; 102:529-530
103. Sonny A, Avitsian R, Hussain MS, et al: Angioedema in the neurointerventional suite. J Clin Anesth 2015; 27:170-174
104. Walsh RM, Bothwell JD: Simulated angioedema in a fresh frozen cadaver: A novel teaching model for airway training. Simul Healthc 2015; 10:378-380
105. Szema AM, Paz G, Merriam L, et al: Modern preoperative and intraoperative management of hereditary angioedema. Allergy Asthma Proc 2009; 30:338-342
106. Jonas N, Mulwafu W, Joubert J: Emergency percutaneous tracheostomy. S Afr J Surg 2007; 45:105-106
107. Kapoor A, Jefferson P, Ball DR: Airway management in angiotensin converting enzyme inhibitor related angioedema. Can J Anaesth 2007; 54:242; author reply 242-243
108. Bonnaud I, Rouaud V, Guyot M, et al: Exceptional stroke-like episodes in a patient with type I autosomal angioedema. Neurology 2012; 78:598-599
109. Kageyama T, Okanoue Y, Takai R, et al: Cardiovascular instability preceded by orolingual angioedema after alteplase treatment. Intern Med 2016; 55:409-412
110. Pahs L, Droege C, Kneale H, et al: A novel approach to the treatment of orolingual angioedema after tissue plasminogen activator administration. Ann Emerg Med 2016; 68:345-348
111. Myslimi F, Caparros F, Dequatre-Ponchelle N, et al: Orolingual angioedema during or after thrombolysis for cerebral ischemia. Stroke 2016; 47:1825-1830
112. Foreman A, He T, Chan Y, et al: Persistent, severe post-Thrombolysis angioedema: Simple management of a difficult problem. Am J Otolaryngol 2015; 36:721-724
113. Kovach TA, Kang DR, Triplett RG: Massive macroglossia secondary to angioedema: A review and presentation of a case. J Oral Maxillofac Surg 2015; 73:905-917
114. Miller DG, Sweis RT, Toerne TS: Penile angioedema developing after 3 years of ACEI therapy. J Emerg Med 2012; 43:273-275
115. Möhrenschlager M, Ring J: Male genital oedema-Allergy and angiooedema in the differential diagnosis. J Eur Acad Dermatol Venereol 2008; 22:369-370
116. Dhairyawan R, Harrison R, Buckland M, et al: Hereditary angioedema: An unusual cause of genital swelling presenting to a genitourinary medicine clinic. Int J STD AIDS 2011; 22:356-357
117. Komen DJ, Doorn MB, Zeegelaar JE: A 22 year old man with acute genital oedema and a swollen ankle. BMJ 2011; 343:d3132
118. Nzeako UC, Longhurst HJ: Many faces of angioedema: Focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol 2012; 24:353-361
119. Ohsawa I, Nagamachi S, Suzuki H, et al: Leukocytosis and high hematocrit levels during abdominal attacks of hereditary angioedema. BMC Gastroenterol 2013; 13:123
120. Miller CW, Krishnaswamy N, Johnston C, et al: Severe asthma and the omalizumab option. Clin Mol Allergy 2008; 6:4